The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hypersomnia Drug-Global Market Insights and Sales Trends 2024
Synopsis
Hypersomnia indicates frequent and excessive daytime sleepiness. It becomes necessary for patients suffering from hypersomnia to take short naps in-between the day time and sleep more than 10 hours at night. However, the naps do not provide any relief. Also, patients may feel disoriented and can have difficulty in moving. Due to hypersomnia patients may have restlessness, loss of appetite hallucinations and slow speech.
The global Hypersomnia Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hypersomnia Drug in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Hypersomnia Drug market. Provigil, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Xyrem segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hypersomnia Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hypersomnia Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hypersomnia Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hypersomnia Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hypersomnia Drug covered in this report include Teva, Jazz Pharmaceuticals, BIOPROJET, AVADEL PHARMACEUTICALS, GlaxoSmithKline, Pfizer, Theranexus, Fisher & Paykel Healthcare and Drive Medical, etc.
The global Hypersomnia Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
Jazz Pharmaceuticals
BIOPROJET
AVADEL PHARMACEUTICALS
GlaxoSmithKline
Pfizer
Theranexus
Fisher & Paykel Healthcare
Drive Medical
Merck
Global Hypersomnia Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hypersomnia Drug market, Segment by Type:
Provigil
Xyrem
Others
Global Hypersomnia Drug market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hypersomnia Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hypersomnia indicates frequent and excessive daytime sleepiness. It becomes necessary for patients suffering from hypersomnia to take short naps in-between the day time and sleep more than 10 hours at night. However, the naps do not provide any relief. Also, patients may feel disoriented and can have difficulty in moving. Due to hypersomnia patients may have restlessness, loss of appetite hallucinations and slow speech.
The global Hypersomnia Drug market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hypersomnia Drug in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Hypersomnia Drug market. Provigil, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Xyrem segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hypersomnia Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hypersomnia Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hypersomnia Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hypersomnia Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hypersomnia Drug covered in this report include Teva, Jazz Pharmaceuticals, BIOPROJET, AVADEL PHARMACEUTICALS, GlaxoSmithKline, Pfizer, Theranexus, Fisher & Paykel Healthcare and Drive Medical, etc.
The global Hypersomnia Drug market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva
Jazz Pharmaceuticals
BIOPROJET
AVADEL PHARMACEUTICALS
GlaxoSmithKline
Pfizer
Theranexus
Fisher & Paykel Healthcare
Drive Medical
Merck
Global Hypersomnia Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hypersomnia Drug market, Segment by Type:
Provigil
Xyrem
Others
Global Hypersomnia Drug market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hypersomnia Drug companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hypersomnia Drug
1.1 Hypersomnia Drug Market Overview
1.1.1 Hypersomnia Drug Product Scope
1.1.2 Hypersomnia Drug Market Status and Outlook
1.2 Global Hypersomnia Drug Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hypersomnia Drug Market Size by Region (2018-2029)
1.4 Global Hypersomnia Drug Historic Market Size by Region (2018-2023)
1.5 Global Hypersomnia Drug Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hypersomnia Drug Market Size (2018-2029)
1.6.1 North America Hypersomnia Drug Market Size (2018-2029)
1.6.2 Europe Hypersomnia Drug Market Size (2018-2029)
1.6.3 Asia-Pacific Hypersomnia Drug Market Size (2018-2029)
1.6.4 Latin America Hypersomnia Drug Market Size (2018-2029)
1.6.5 Middle East & Africa Hypersomnia Drug Market Size (2018-2029)
2 Hypersomnia Drug Market by Type
2.1 Introduction
2.1.1 Provigil
2.1.2 Xyrem
2.1.3 Others
2.2 Global Hypersomnia Drug Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hypersomnia Drug Historic Market Size by Type (2018-2023)
2.2.2 Global Hypersomnia Drug Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hypersomnia Drug Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hypersomnia Drug Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hypersomnia Drug Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hypersomnia Drug Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hypersomnia Drug Revenue Breakdown by Type (2018-2029)
3 Hypersomnia Drug Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Hypersomnia Drug Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hypersomnia Drug Historic Market Size by Application (2018-2023)
3.2.2 Global Hypersomnia Drug Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hypersomnia Drug Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hypersomnia Drug Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hypersomnia Drug Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hypersomnia Drug Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hypersomnia Drug Revenue Breakdown by Application (2018-2029)
4 Hypersomnia Drug Competition Analysis by Players
4.1 Global Hypersomnia Drug Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hypersomnia Drug as of 2022)
4.3 Date of Key Players Enter into Hypersomnia Drug Market
4.4 Global Top Players Hypersomnia Drug Headquarters and Area Served
4.5 Key Players Hypersomnia Drug Product Solution and Service
4.6 Competitive Status
4.6.1 Hypersomnia Drug Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Teva
5.1.1 Teva Profile
5.1.2 Teva Main Business
5.1.3 Teva Hypersomnia Drug Products, Services and Solutions
5.1.4 Teva Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.1.5 Teva Recent Developments
5.2 Jazz Pharmaceuticals
5.2.1 Jazz Pharmaceuticals Profile
5.2.2 Jazz Pharmaceuticals Main Business
5.2.3 Jazz Pharmaceuticals Hypersomnia Drug Products, Services and Solutions
5.2.4 Jazz Pharmaceuticals Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.2.5 Jazz Pharmaceuticals Recent Developments
5.3 BIOPROJET
5.3.1 BIOPROJET Profile
5.3.2 BIOPROJET Main Business
5.3.3 BIOPROJET Hypersomnia Drug Products, Services and Solutions
5.3.4 BIOPROJET Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.3.5 AVADEL PHARMACEUTICALS Recent Developments
5.4 AVADEL PHARMACEUTICALS
5.4.1 AVADEL PHARMACEUTICALS Profile
5.4.2 AVADEL PHARMACEUTICALS Main Business
5.4.3 AVADEL PHARMACEUTICALS Hypersomnia Drug Products, Services and Solutions
5.4.4 AVADEL PHARMACEUTICALS Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.4.5 AVADEL PHARMACEUTICALS Recent Developments
5.5 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.5.2 GlaxoSmithKline Main Business
5.5.3 GlaxoSmithKline Hypersomnia Drug Products, Services and Solutions
5.5.4 GlaxoSmithKline Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.5.5 GlaxoSmithKline Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Hypersomnia Drug Products, Services and Solutions
5.6.4 Pfizer Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Theranexus
5.7.1 Theranexus Profile
5.7.2 Theranexus Main Business
5.7.3 Theranexus Hypersomnia Drug Products, Services and Solutions
5.7.4 Theranexus Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.7.5 Theranexus Recent Developments
5.8 Fisher & Paykel Healthcare
5.8.1 Fisher & Paykel Healthcare Profile
5.8.2 Fisher & Paykel Healthcare Main Business
5.8.3 Fisher & Paykel Healthcare Hypersomnia Drug Products, Services and Solutions
5.8.4 Fisher & Paykel Healthcare Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.8.5 Fisher & Paykel Healthcare Recent Developments
5.9 Drive Medical
5.9.1 Drive Medical Profile
5.9.2 Drive Medical Main Business
5.9.3 Drive Medical Hypersomnia Drug Products, Services and Solutions
5.9.4 Drive Medical Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.9.5 Drive Medical Recent Developments
5.10 Merck
5.10.1 Merck Profile
5.10.2 Merck Main Business
5.10.3 Merck Hypersomnia Drug Products, Services and Solutions
5.10.4 Merck Hypersomnia Drug Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Recent Developments
6 North America
6.1 North America Hypersomnia Drug Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hypersomnia Drug Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hypersomnia Drug Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hypersomnia Drug Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hypersomnia Drug Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hypersomnia Drug Market Dynamics
11.1 Hypersomnia Drug Industry Trends
11.2 Hypersomnia Drug Market Drivers
11.3 Hypersomnia Drug Market Challenges
11.4 Hypersomnia Drug Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
